Navigation Links
Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
Date:11/2/2011

ovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis Pharmaceuticals and the discovery, development and potential of ISIS-GCGRRx and ISIS-GCCRRx for the treatment of type 2 diabetes.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of mipomersen, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2010 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other document
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
2. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
3. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
4. CareFusion Initiates Class I Recall of EnVe Ventilators
5. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
6. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
10. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
11. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 /CNW/ - Health Minister Rona Ambrose today ... for donation over $2.5 million in personal protective equipment (PPE) ... global response to the Ebola outbreak in West ... shortage of equipment in the affected countries and has appealed ... in the affected countries. Personal protective equipment ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics ... specialty pharmaceutical company with a focus on Omega-3 ... today that the Board of Directors approved the ... an advisor at the close of business on Friday, ... of 1,000,000 common shares of the Company were ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... affects persons of all ages, but most commonly ... condition characterized by narrowing of the airways, leading ... the lungs come into contact with endogenous and ... of events, such as swelling of the airways, ...
Breaking Medicine Technology:Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 2Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 3Pivotal Therapeutics Grants Incentive Stock Options 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5
... VIVUS, Inc. (Nasdaq: VVUS ) announced today ... the U.S. Food and Drug Administration (FDA) regarding its ... QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL ... approved in its present form.  The application seeks the ...
... Corporation (Nasdaq: THOR ), a world leader ... and restore failing hearts, said revenues from continuing operations ... versus the third quarter of 2009. Results ... first nine months of 2010 and 2009 exclude contributions ...
Cached Medicine Technology:FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 2FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 4FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16
(Date:9/16/2014)... Today The FSH Society, a world leader in ... Song,” featuring luminary pianist Steven Blier and two-time Grammy Award ... 2014 at the Tappan Hill Mansion, located on the former ... is proud to welcome Blier, who performs each year, and ... research. , FSHD, one of the most prevalent types of ...
(Date:9/16/2014)... Norfolk, VA (September 16, 2014) – ... desserts, announced today the launch of a limited edition ... October. In support of the American Cancer Society, an ... charitable donation in 2014 as well as help to ... among women in the United States. , The ...
(Date:9/16/2014)... 2014 (HealthDay News) -- Key connections between brain ... people with attention deficit hyperactivity disorder (ADHD), according ... within and between certain brain networks control ... the ability to focus on external tasks. This ... light on why those with ADHD are easily ...
(Date:9/16/2014)... 16, 2014 After working together for eight ... the premier fertility centers in the late 1990s and early ... to their hometown of New York City to launch Chelsea ... Genetics Labs. , Chelsea Fertility NYC offers full service ... in the New York Tri-State Area, and provides equal access ...
(Date:9/16/2014)... Dr. Randy Carlson and The Intentional Living ... Marriage event is coming to the Phoenix and Tucson ... better communicate, increase intimacy and have more fun with their ... and learning to strengthen your marriage and to rediscover intimacy,” ... Bible Church (Mesa), Saturday, Sept. 27 – Glendale Church of ...
Breaking Medicine News(10 mins):Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 2Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 3Health News:Lucy’s Joins Fight Against Breast Cancer With Launch Of Limited Edition Packaging And Charitable Donation 2Health News:Lucy’s Joins Fight Against Breast Cancer With Launch Of Limited Edition Packaging And Charitable Donation 3Health News:Study Sees Differences in Brain Connections of Kids With ADHD 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:The Intentional Living Center Introduces the Love Your Marriage Night Featuring Dr. Randy Carlson in Arizona 2
... data is showing a dramatic,reduction in the accidental ... more on one group,s 20-year effort to protect ... from Safe Kids Worldwide at:, http://media.medialink.com/WebNR.aspx?story=35058 , ... and,photos for free and unrestricted use at ...
... Brown & Toland Medical Group,today announced a strong financial ... on total revenues of $235 million., The medical ... performance and other related bonuses from health plans. The,medical ... $8.2,million in bonus payments to eligible physicians. In 2007 ...
... seem to cause drop in heart rate variability, researchers ... of a small study show that the electromagnetic field ... babies, Italian researchers report. , Whether these changes in ... could have implications for premature infants who can spend ...
... the Only Treatment Approved to Both Reduce Exacerbations ... ... 30 The,U.S. Food and Drug Administration today approved Advair ... powder),for the reduction of exacerbations in patients with chronic obstructive,pulmonary ...
... better way to distinguish acute leukemia patients who require aggressive ... therapy for cure., The study is published in the May ... an accompanying editorial. , Researchers say that changes in levels ... the kinds and amount of proteins they make, might predict ...
... April 30 Allscripts, the leading,provider of clinical ... improve healthcare, today announced results for the three,months ... ), Total revenue for the three months ... $65.0 million for the same period last year,increasing ...
Cached Medicine News:Health News:Brown & Toland Announces 2007 Financial Results 2Health News:Incubators Affect Newborns' Heart Rates 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4Health News:Molecular change may reveal risk of leukemia relapse 2Health News:Molecular change may reveal risk of leukemia relapse 3Health News:Allscripts Reports First Quarter 2008 Results 2Health News:Allscripts Reports First Quarter 2008 Results 3Health News:Allscripts Reports First Quarter 2008 Results 4Health News:Allscripts Reports First Quarter 2008 Results 5Health News:Allscripts Reports First Quarter 2008 Results 6Health News:Allscripts Reports First Quarter 2008 Results 7Health News:Allscripts Reports First Quarter 2008 Results 8Health News:Allscripts Reports First Quarter 2008 Results 9Health News:Allscripts Reports First Quarter 2008 Results 10
Inquire...
... Roches patented polymerase chain reaction (PCR) ... technology, is an essential component of Roches ... PCR allows minute amounts of selected unique ... into billions of copies (that is, to ...
... Introducing BenchMark XT® the only fully ... flexibility you need to expand your ... improve your slide turnaround time. All ... choose how to use the BenchMark ...
... Reicherts new ATP Auto Non-Contact Tonometer / ... / pachymeter, combining the measurement of IOP ... response to numerous clinical studies that have ... thickness as well as intraocular pressure in ...
Medicine Products: